SoftOx Solutions AS - Asset Resilience Ratio

Latest as of September 2025: 17.07%

SoftOx Solutions AS (SOFTX) has an Asset Resilience Ratio of 17.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see SoftOx Solutions AS (SOFTX) total assets.

Liquid Assets

Nkr20.06 Million
≈ $2.11 Million USD Cash + Short-term Investments

Total Assets

Nkr117.52 Million
≈ $12.37 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how SoftOx Solutions AS's Asset Resilience Ratio has changed over time. Read SoftOx Solutions AS (SOFTX) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down SoftOx Solutions AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See SoftOx Solutions AS (SOFTX) liquidity interval to measure how many days the company can operate on defensive assets alone.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr20.06 Million 17.07%
Short-term Investments Nkr0.00 0%
Total Liquid Assets Nkr20.06 Million 17.07%

Asset Resilience Insights

  • Good Liquidity Position: SoftOx Solutions AS maintains a healthy 17.07% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

SoftOx Solutions AS Industry Peers by Asset Resilience Ratio

Compare SoftOx Solutions AS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Biotechnology 0.00%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 10.17%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for SoftOx Solutions AS (2016–2024)

The table below shows the annual Asset Resilience Ratio data for SoftOx Solutions AS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 8.68% Nkr10.51 Million
≈ $1.11 Million
Nkr121.14 Million
≈ $12.75 Million
+0.81pp
2023-12-31 7.87% Nkr7.65 Million
≈ $805.24K
Nkr97.24 Million
≈ $10.23 Million
-1.00pp
2022-12-31 8.87% Nkr6.91 Million
≈ $726.82K
Nkr77.83 Million
≈ $8.19 Million
-44.29pp
2021-12-31 53.17% Nkr56.98 Million
≈ $6.00 Million
Nkr107.18 Million
≈ $11.28 Million
+13.31pp
2020-12-31 39.86% Nkr34.80 Million
≈ $3.66 Million
Nkr87.31 Million
≈ $9.19 Million
-32.54pp
2019-12-31 72.40% Nkr76.00 Million
≈ $8.00 Million
Nkr104.96 Million
≈ $11.05 Million
+67.12pp
2018-12-31 5.29% Nkr1.24 Million
≈ $130.12K
Nkr23.39 Million
≈ $2.46 Million
-49.80pp
2017-12-31 55.09% Nkr17.10 Million
≈ $1.80 Million
Nkr31.04 Million
≈ $3.27 Million
+51.68pp
2016-12-31 3.41% Nkr301.99K
≈ $31.78K
Nkr8.86 Million
≈ $932.31K
--
pp = percentage points

About SoftOx Solutions AS

OL:SOFTX Norway Biotechnology
Market Cap
$26.87 Million
Nkr255.36 Million NOK
Market Cap Rank
#24232 Global
#224 in Norway
Share Price
Nkr0.10
Change (1 day)
-1.74%
52-Week Range
Nkr0.05 - Nkr0.16
All Time High
Nkr112.00
About

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx So… Read more